13 March 2020 | News
AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19
Image credit- shuttershock.com
AbCellera and Eli Lilly and Company have announced that they have entered into an agreement to co-develop antibody (Ab) products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.
The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution. If successful, Lilly is ready to work with global regulators to bring a treatment to patients.